[1] OMS. Centre des medias, La santé mentale : renforcer notre action, Aide-mémoire N °220, septembre 2010
http://www.who.int/mediacentre/factsheets/fs220/fr, [2] OMS. http://www.emro.who.int/health-topics/suicide/
[3] Anderson Gerard F. et al Expanding priorities – confronting chronic disease in countries with low income. New England Journal of Medicine, 2007, 356 :209-211.
[4] WHO Mental Health Global Action Programme (mhGAP), 2002
[5] World Economic Forum and Harvard School of Public Health. T he global economic burden of non-communicable disease. September 2011
[6] OMS. Santé mentale Faits et chiffres, Santé mentale : un état de bien-être
http://www.who.int/features/factfiles/mental_health/mental_health_facts/fr/index7.html [7] OMS. 66ème Assemblée mondiale de la santé. Projet de plan d‟action global pour la santé mentale 2013-2020. A66/10Rev.1, 16 mai 2013
[8] OMS. Rapport sur la santé dans le monde, 2001. La santé mentale : nouvelle conception, nouveaux espoirs
http://www.who.int/whr/2001/en/whr01_fr.pdf
[9] Stahl SM, muntner N, lemoine P. psychopharmacologie essentielle bases neuroscientifiques et applications pratiques. Paris : Médecine sciences publications ;2010 [10] Article pharmaceutiques, n° 493 Février 2010 de Diane Lévy-Chavagnat Praticien hospitalier, vice-présidente du COMEDIMS, Centre hospitalier Henri Laborit, Poitiers (thymorégulateur une famille en mouvement)
[11] Manuel diagnostique et statistique des troubles mentaux (Diagnostic and Statistical Manual of Mental Disorders ou DSM), quatrième édition. Manuel de référence utilisé
140
internationalement pour les recherches statistiques et pour diagnostiquer les troubles psychiatriques.
[12] plan stratégique de promotion la santé mentale des enfants adolescent et jeunes http://santejeunes.ma/wp-content/uploads/2018/02/08.pdf
[13] Ministère de la santé marocain Enquête nationale sur les prévalences des troubles mentaux en population générale, (ENPTM 2003-2006).
[14] Enquête nationale du ministère de la santé publique :‟Situation épidémiologique des troubles mentaux et toxicomanies au Maroc‟ (Repère médical, n° 9, 2006
[15] http://dx.doi.org/10.1016/j.respe.2017.03.098
[16] Rouillons F. Epidémiologie du trouble bipolaire. L‟Encéphale 1997; (Suppl 1) : 7-11. [17] Hirschfeld RM et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64: 53-9.
[18] Douki S., Ben Zineb S., Nacef F. Le trouble bipolaire dans les pays du sud. L‟Encéphale 2005; 31: 53,7.
[19] Ministère de la sante, Enquête nationale : prévalence des troubles mentaux dans la population générale en 2003. oms 2007
[20] Ghachem R. et al. Approche du Trouble Bipolaire : comparaison entre deux populations de patients hospitalisés en France et en Tunisie. Annales Médico Psychologiques, 2006 ; 164 : 329–336.
[21]. Rouillons F. Epidémiologie des troubles psychiatriques. Annales Médico psychologique 2008 ; 166 : 63- 70.
[22] Godart N. Signes cliniques de vulnérabilité bipolaire à l‟adolescence. L‟Encéphale, 2005; 31: 3-5.
[23] Lonnquist JE, Verskasalo M, Haukka J, Nyman K, Tiihonen J, Laaksonen I, et al. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts. Abnorm
141
Psychol 2009;118:418–23.
[24] Elbogen EB, Johnson SC. The intricate link between violence and mental disorder: Results from the National Epidemiologic Survey on Alcohol and relate Conditions. Arch Gen Psychiatry 2009;66:152–61
[25] Delay J, Deniker P, Harl JM. Utilisation en thérapeutique psychiatrique d‟une phénothiazine d‟action centrale élective. Ann Med Psychol 1952;110(T.1):112–7.
[26] Delay J, Deniker, Harl J. Traitement des états d‟excitation et d‟agitation par une méthode médicamenteuse dérivé de l‟hibernothérapie. Ann Med Psychol 1952;110:267–73. [27] Delay J, Deniker P, Harl JM. Traitement d‟états confusionnels par le chlorhydrate de diméthylaminopropyl N chlorophénothiazine. Ann Med Psychol 1952;110:398–463.
[28] Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Austr 1949;36:349–52.
[29] Teulié M, Follin, Beguin. étude de l‟action des sels de lithium dans les états d‟excitation psychomotrice. Encéphale 1955;44:266–85.
[30] Daumezon G, Cassan L. Essai de thérapeutique abortive d‟accés maniacodépressifs par le 2339 RP. Ann Med Psychol 1943;101(T.II):432–43.
[31] Favarel-Garrigues B, Favarel-Garrigues JC, Bourgeois ML. Deux cas d‟intoxication par le carbonate de lithium. Ann Med Psychol 1972; 130:253–7.
[32] Gay C, Loo H, Langer SZ. Lithium treatment increases norpinephrine turnover in the plasma of healthy subjects. Psychopharmacology 1988;94:521–6.
[33] Verdoux H, Bourgeois ML. A case of lithium neurotoxicity with irreversible cerebellar syndrome. Brief Report. 1990:761–2.
[34] Verdoux H, Bourgeois ML. Conséquence à court terme de l‟interruption d‟un traitement par sels de lithium. Encéphale 1993;XIX:645–50
[35] Bauer M, Grof P, Muller-Oerlinghause B. Lithium in neurospsychiatry. In: The comprehensive guide. UK: IGSLI Informa; 2006. 532 p.
142
[36] Despinoy M, Romeuf Jde. Emploi des sels de lithium en thérapeutique psychiatrique. CR 49e Congrés des Alién Neurol de langue franc¸aise (Rennes, 1951). Paris: Masson; 1952. [37] Moncrief J. Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995;167:569–74.
[38] Bourgeois ML. Les médicaments thymorégulateurs et leurs associations dans le traitement des troubles bipolaires. PSN 2004;II(numeéro 4):25–31.
[39] Bourgeois ML. Les médicaments thymorégulateurs, un mythe pharmacologique ? Encéphale 2005;31:109–11
[40] Verdoux H. Les thymorégulateurs. Paris: Lavoisier-Flammarion; 2013
[41] Yvonneau M. Le carbonate de lithium en thérapeutique psychiatrique. Evol Psychiatr 1970;XXXV:407–26
[42] Dufour H. Les sels de lithium en thérapeutique psychiatrique.[Thèse médecine] Université de Marseille; 1970
[43] Delay J, Deniker P. Méthodes chimiothérapiques en psychiatrie, les nouveaux médicaments psychotropes. Paris: Masson; 1961.
[44] Cade JF. John Frederick Joseph Cade : family memories on the ocaasion of the 50th of his discovery of the use of lithium in mania. 1949. Aut N Z J psychiatry 1999 ; 33 :615 4 âges following
[45] Schou M. Lithium treatment at 52. J affect Disord 2001 ; 67 :21-32 [46] Schou M. (50 years lithium treatment ). Encephale 2000 ;26 :2-6.
[47] Schou M, Amdisen A, Trap- Jensen J. Lithium poisonning. Am J psychiatry
[48] schou M, Aùdisen A, Trap-Jensen J. ( Severe lithium poisonning. Report on 8 cases). Nord Med 1967 ;77 :831-7
143
[49] Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium : double blind discontinuation in manic-depressive and recurrent depressive disordes. Lancet 1970 ; 2 :326-30.
[50] Coppen A , Noguera R, Bailey J, et al. Prophyalactic lithium in affective disorders. Controlled trial. Lancet 1971 ; 2 :275-9
[51] Coppen A, Peet M, Bailey J, et al. Double -blind and open prospective studies on lithium prophylaxis in affective disorders. Psychiatr Neurol Neurochir 1973 ;76 :51-10
[52] http://solidarites-sante.gouv.fr/IMG/doc/les-medicaments-psychotropes.doc
[53] Caulin C, Vidal SA. Vidal Recos recommandations en pratique, 2014 : 175 stratégies thérapeutiques. Issy-les-Moulineaux : Vidal ;2013 .
[54] Haute Autorité de santé. Synthése d‟avis de la commission de la transparence : Xeroquel LP. 2011.
[55] Franck N, Thibaut F. Modalités d‟utilisation des neuroleptiques. EMC – Psychiatr. 2005 Nov ; 2(4) : 300-39
[56] Meunier H, Carraz G, Neunier Y, et al. Pharmacodynamic properties of Ndipropylacetic acid. Therapie 1963; 18: 435-8
[57] Garnier M, Delamare V, Delamare J, Delamare F, Gélis-Malville É, Delamare L, et
al. Dictionnaire illustré des termes de médecine. Delamare J, editor. Paris, France: Maloine,
2009; 2009. xxxiv+1054 p.
[58] European medicines agency. Pharmacovigilance risk assessment commitee (PRAC). Minutes of the meeting on 3-6 November 2014. Aripiprazole - Abilify. 4 décembre 2014: 17-18.
[59] Assurance maladie. Choix d‟une benzodiazépine dans les troubles anxieux ou les troubles du sommeil chez le sujet de plus de 65 ans polypathologique ou de plus de 75 ans .2014
[60] Agence francaise de sécurité sanitaire des produits de santé. Rapport d‟experise : Etat des lieux de la consommation des benzodiazépine en France.2012 jan.
144
[61] https://www.encephale.com/content/download/87364/1523969/version/1/file/main.pdf [62] Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010 ; 32 : 19-29.
[63] Malhi GS, Adams D, Cahill CM et al. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs 2009 ; 69 : 2063-101.
[64] Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007 ; 64 : 442-55.
[65] Smith LA, Cornelius V, Warnock A et al. Acute bipolar mania : a systematic review and meta-analysis of co-therapy vs monotherapy. Acta Psychiatr Scand 2007 ; 115 : 12-20. [66] Smith LA, Cornelius V, Warnock A et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disorders 2007 ; 9 : 551-60
[66] Cipriani A, Pretty H, Hawton K et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005 ; 162 : 1805-19.
[67] Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry 2009 ;43 : 1096-104.
[68] Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 ; 60 : 1079-88.
[69] Van der Loos ML, Mulder PG, Hartong EG et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009 ; 70 : 223-31.
145
[70] Young LT, Joffe RT, Robb JC et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000 ; 157 : 124-6.
[71] Goodwin FK. Preventing inpatient suicide. J Clin Psychiatry 2003 ; 64 : 12-3. /
Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the
management of bipolar disorder. J Clin Psychiatry 2003 ; 6 : 18-24. / Goodwin FK, Goldstein MA. Optimizing lithium treatment in bipolar disorder: a review of the literature and clinical recommendations. J Psychiatr Pract 2003 ; 9 : 333-43. /Goodwin FK, Jamison KR. Manic-depressive illness: Oxford University Press New York, 1990.
[72] Malhi GS. The impact of lithium on bipolar disorder. Bipolar Disord 2009 ; 11 : 1-3. [73] Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 ; 60 : 392-400. Erratum appears in Arch Gen Psychiatry. 2004 Jul ; 61 : 680.
[74] Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder [see comment]. J Clin Psychiatry 2003 ; 64 : 1013-24.
[75] Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010 ; 375 : 385-95.
[76] Geddes JR, Rendell JM, Goodwin GM. BALANCE : a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry 2002 ; 1 : 48-51.
[77] Malhi GS, Adams D, Lampe L et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009 : 27-46.
[78] Kleindienst N, Greil W. Lithium in the long term treatment of bipolar disorders. Eur Arch Psychiatry Clin Neurosci 2003 ; 253 (3) : 120-5.
[79] Gay C. Pratiques de la lithiothérapie. Consensus et controverses. Psychiatrie pratique de l‟encéphale. Paris : Doin, 1997.
146
[80] LE DICTIONNAIRE VIDAL. Paris : Éditions du Vidal, 2005.
[81] Salloum IM, Corneilius JR, Daley DC et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism : a double-blind placebo-controlled study. Arch Gen Psychiatry 2005 ;62 (1) : 37-45.
[82] Ghaemi SN, Bery DA, Klugman J et al. Oxcarbazepine treatmentof bipolar disorder. J Clin Psychiatry 2003 ; 64 (8) : 943-5.
[83] Fischer JH, Barr AN, Paloucek FP, Dorociak JV, Spunt AL. Effect of food on the serum concentration profile of enteric-coated valproic acid. Neurology 1988;38:1319–22. [84] Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977;21:736–43.
[85] De Vivo DC, Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5:134–41.
[86] Jacob C, Belleville F. L-carnitine: métabolisme, fonctions et intérêt en pathologie. Pathol Biol 1992;40:910–9.
[87] Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995;65:211–4.
[88] Lehninger AL, Nelson DL, Cox MM. Chapitre 16. Oxydation des acides gras. 2e édition. Principes de biochimie. NewYork:MédecineSciences Flammarion; 1994. p. 479–505. [89] Li J, Norwood DL, Mao LF, Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry 1991;30:388–94.
[90] Silva MF, Ruiter JP, Overmars H, Bootsma AH, Van Gennip AH, Jacdos C, et al. Complete beta-oxydation of valproate: cleavage of oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 2002;262:755–60.
[91] Murakami K, Sugimoto T, Nishida N, KobayashiY, Kuhara T, Matsumoto I. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev 1992;14:178–81.
147
[92] Sugimoto T, Muro H, Woo M, Nishida N, Murikami K. Metabolite profiles in patients on high-dose valproate monotherapy. Epilepsy Research 1996;25:107–12.
[93] Coulter DL. Carnitine, valproate, and toxicity. J Child Neurol 1991;6: 7–14.
[94] Hiraoka A, Arato T, Tominaga I. Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs. Biol Pharm Bull 1997;20:91–3.
[95] Sugimoto T, Muro H, Woo M, Murakami K, Nishida N, Sasaki T. Significance of the administration of L-carnitine with valproate therapy: determination of urinary valproylcarnitine. No To Hattatsu 1995;27(suppl):S129.
[96] Hirose S, Mitsudome A, Yasumoto S, Ogawa A, Muta Y, Tomoda Y. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;5:1–5. [97] Camina MF, Rozas I, Castro-Gago M, Paz JM, Alonso C, Rodriguez- Segade S. Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology 1991;41:1444–8.
[98] Spiller AH, Krenzelok EP, Klein-SchwarzW,Winter ML,Weber JA, Sollee DR, et
al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin
Toxicol 2000;38:755–60.
[99] Mortensen PB, Hansen HE, Pedersen B, Hartmann-Andersen F, Husted SE. Acute valproate intoxication : biochemical investigations and haemodialysis treatment. Int J Clin Pharmacol Ther Toxicol 1983;21:64–8.
[100] Andersen GO, Ritland S. Life threatening intoxication with sodium valproate. Clin Toxicol 1995;33:279–84.
[101] LoscherW, Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 1983;226:845–54.
[102] Dupuis RE, Lichtman SN, Pollack GM.Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf 1990;5:65–71.
148
[103] König A, Siemens H, Bläker F, Boenigk E, Gross-Selbeck G, Hanefeld F. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005–15.
[104] Sugimoto T, Araki A, Nishida N, Sakane Y, Woo M, Takeuchi T. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation. Epilepsia 1987;28:373–7.
[105] Thurston JH, Hauhart RE. Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme-A metabolism by cotreatment with panthothenate and carnitine in developing mice: possible clinical significance. Pediatr Res 1992;31:419–23. [106] Triggs WJ, Bohan TP, Lin SN,Willmore LJ. Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol 1990;47: 1131–3.
[107] Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, et
al. Effects of the polytherapy with phenytoin, carbamazepine, and stiripentol on formation of
4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48:225– 35.
[108] Baillie J, Baillie TA. Incidental microvesicular steatosis due to valproic acid anticonvulsivant therapy. Am J Gastroenterol 1992;87: 1225–6.
[109] Sugimoto T, Muro H, Woo M, Nishida N, Murikami K. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia 1996;37:1200–3.
[110] Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990;31:346–52.
[111] Marini AM, Zaret BS, Randolph Beckner R. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 1988;38:365–71.
[112] Bolanos JP, Medina JM. Mini review. Effect of valproate on the metabolism of the central nervous system. Life Sci 1997;60:1933–42.
149
[113] Lam CW, Lau CH,Williams JC, ChanYW,Wong LJC. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997;156: 562–4.
[114] Martin G, Michoudet C, Baverel G. Stimulation of glutamine metabolism by the antiepileptic drug, sodium valproate, in isolated dog kidney tubules. Bioch Pharmacol 1989;38:3947–52.
[115] Dumoulin A, Lapostolle F, Adnet F, Muzynski J, Baud FJ. Acidose et hyperlactatémie lors des intoxications aiguës par le valproate de sodium. Presse Med 1997;26:555–7.
[116] Johnson DW, Harrison JR, Norton WA, Poulos A, Robertson EF. Plasma cis-dec-4-enoic acid measured by isotope dilution mass spectrometry; an improved assay to diagnose medium-chain acyl- CoA dehydrogenase deficiency. J Inherit Metab Dis 1994;17:554–9. [117] Litovitz TL, Felberg L, White S, Klein-Schwartz W. 1995 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1996;14:487–537.
[118] Bédry R, Parrot F, Janvier L, Hilbert G, Ould-Larbi K, Favarel- Garrigues JC, et
al. Perturbationsmétaboliques induites par les intoxications au valproate de sodium
(Depakine®). Intérêt de la supplémentation en carnitine. Réan Urg 1997;6:771 (abstract). [119] Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate. Lancet 1982;2:1306. [120] Karlsen RL, Kett K, Henriksen O. Intoxication with sodium valproate. A case-report. Acta Med Scand 1983;213:405–6.
[121] Fernandez MC, Walter FG, Peterson LR, Walkotte SM. Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. Clin Toxicol 1996;34:437–9.
[122] Triggs WJ, Gilmore RL, Millington DS, Cibula J, Bunch TS, Harman E. Valproate-associated carnitine deficiency and malignant cerebral oedema in the absence of hepatic failure. Int J Clin Pharmacol Ther 1997;35:353–6.
150
[123] Sztajnkrycer D. Valproic acid toxicity: overview and management. Clin Toxicol 2002;40:789–801.
[124] Schnabel R, Rambeck B, Janssen F. Fatal intoxication with sodium valproate. Lancet 1984;1:221–2.
[125] Khoo SH, Leyland MJ. Cerebral oedema following acute sodium valproate overdose. J Toxicol Clin Toxicol 1992;30:209–14.
[126] Berthelot-Moritz F, Chadda K, Chanavaz I, Leroy JP, Droy JM, Bonmarchand G,
et al. Fatal sodium valproate poisoning. Intensive Care Med 1997;23:599.
[127] Sasso E, Delsoldato S, Negrotti A, Mancia D. Reversible valproateinduced extrapyramidal disorders. Epilepsia 1994;35:391–3.
[128] Shill HA, Fife TD. Valproic acid toxicity mimicking multiple system atrophy. Neurology 2000;55:1936–7.
[129] Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998;39:27–32.
[130] Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem 1988;34:890–7. [131] Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JL, et
al. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979;5:142–4.
[132] Bohan TP,Helton E, McDonald I, König S, Gazitt S, Sugimoto T, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405–9.
[133] McGarry JD, Foster DW. An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Research 1976;17:277–81.
[134] Beauchamp J, Olson K.Valproic acid overdoses: a retrospective study comparing serum drug levels and the incidence of adverse outcomes. J Toxicol Clin Toxicol 1999;37:637–8.
151
[135] Lejonc JL, Elkharrat D, Lapandry C, Leblanc J-P, Robert R, Saint- Martin J, et
al. Épuration digestive lors des intoxications aiguës. Rean Urg 1993;2 bis:169–75.
[136] Tank JE, Palmer BF. Simultaneous “in series” hemodialysis and hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate acid overdose.Am J Kidney Dis 1993;22: 341–4.
[137] De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli RS, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39:1216–25.
[138] http://ansm.sante.fr/S-informer/Informationsde-securite-Lettres-aux-professionnels-de-sante/ Nouvelles conditions-de-prescription-et-de-delivrance- des-specialites-a-base-de-valproate-et- derives-Depakine-R-Depakote-R-Depamide- R-Micropakine-R-et-generiques-du-fait-desrisques- lies-a-leur-utilisation-pendant-la-grossesse- Lettre-aux-professionnels-de-sante
[139] REVUE FRANCOPHONE DES LABORATOIRES - DÉCEMBRE 2016 - N°487 [140] DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet 1984;19:473–81.
[141] Mutlu-Albayrak H, Bulut C, Çaksen H. Fetal valproate syndrome. Pediatr Neonatol 2016 [in press. http://dx.doi.org/10.1016/j. pedneo.2016.01.009].
[142] Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs- Cantrell DT,
Cohen M, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic
drugs. N Engl J Med 2009;360 (16):1597–605.
[143] Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et
al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a
prospective
observational study. Lancet Neurol 2013;12(3):244–52.
[144] Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy
152
(an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy. Soc Neurol 2009;73(2):133–41. [145] Prévos-Morgant M, Petit J, Grisoni F, André-Obadia N, Auvin S, Derambure P. A national framework for educational programs in epileptic patients, children and adults. Rev Neurol 2014;170(8–9):497–500.
[146] The New England Journal of Medicine, Massachusetts Medical Society Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations
[147] Lawther Lorna, Dolk Helen, Sinclair Marlene, Morrow Jim.The Preconception Care Experiences of Women with Epilepsy on Sodium Valproate.SEIZURE: European Journal of Epilepsy https://doi.org/10.1016/j.seizure.2018.05.003
[148] Sanofi-eventis-maroc ,departement pharmacovigilence sanofi ,lettre d‟information : acide valproique, https://www.medias24.com/MAROC/SOCIETE/166360-Sante.-Maroc-vigilance-renforcee-sur-la-Depakine.html
[149] Lis-Balchin M, Hart S. Studies on the mode of action of the essential oil of lavender (Lavandula angustifolia P. Miller). Phytother Res, 1999;13(6): 540
[150] Franchomme P, Jallois R, Pénoël D. L‟aromathérapie exactement: encyclopédie de l‟utilisation thérapeutiques des extraits aromatiques. Edition Roger Jollois, 2001
[151] Couic Marinier F. Huiles essentielles: l‟essentiel. Conseils pratiques en aromathérapie pour toute la famille au quotidien. 2009
[152] Gérault G, Mary R. Le guide de l‟aromathérapie. Edition Albin Michel, 2009
[153] Kasper S, Gastpar M, Müller WE, Voltz HP, Möller HJ, Dienel A, Schläfke S.
Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of
„subsyndromal „ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol, 2010; 25 (5): 277- 287
153
[154] Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry, 2005; 17 (2): 65-69
[155] Allgulander C, Hartford J, Russel J, Balll S, Erickson J, Raskin J, Rynn M. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin, 2007; 23 (6): 1245-1252
[156] Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedecine, 2010; 17 (2): 94-99
[157] Sayorwan W, Siripornpanich V, Piriyapunyaporn T, Hongratanaworakit T,
Kotchabhakdi N, Ruangrungsi N. The Effects of Lavender Oil Inhalation on Emotional
States, Autonomic Nervous System, and Brain Electrical Activity. J Med Assoc Thai, 2012; 95 (4): 598- 606
[158] Angiosperm Phylogeny Group. An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants : APG III. Botanical Journal of the Linnean Society. 2009, 161, 105-121.
[159] Crété P., Précis de botanique-Systématique des angiospermes. Paris, Masson, 1965, tome 2, 182-183.
[160] Cronquist Arthur. The Evolution and Classification of Flowering Plants. Bronx, The New York Botanical Garden, 1988, Second Edition 555 p.
[161] Hammerness P., Basch E., Ulbricht C., Barrette E., Foppa I., Basch S., Bent S.,
Boon H. and Ernst E. St John’s Wort : A Systematic Review of Adverse Effects and Drug
Interactions for the Consultation Psychiatrist. Psychosomatics. 2003, 44, 271-282.